Bybit, one of the world’s top three crypto exchanges by trading volume, today celebrates a monumental milestone: surpassing 30 million registered users globally. This remarkable achievement comes alongside a period of exceptional growth, solidifying Bybit as a frontrunner in the blockchain industry.
Market Share Soars, User Trust Flourishes
Bybit’s market share in spot trading has skyrocketed from 2% in 2023 to a staggering 9.3% in 2024, a nearly 400% surge according to the latest Kaiko Research quarterly report. This significant leap from the previous year’s 7.3% firmly establishes Bybit as a leader in cryptocurrency exchange.
Bybit attributes this growth to its unwavering commitment to user security and trust. The company prioritizes asset safety through the regular publication of proof-of-reserve audits, ensuring transparency and accountability with user funds. Additionally, Bybit boasts an impeccable security record, with no major breakdowns or hacking incidents since its inception in 2018.
This dedication to security and transparency is further validated by industry recognition. Bybit has received a perfect 10/10 Trust Score from CoinGecko and an ‘AA’ rating in the recent CCData Crypto Exchange Benchmark Report.
“Reaching 30 million registered users is a humbling achievement, and it wouldn’t be possible without the unwavering support of our vibrant global crypto community,” said Ben Zhou, Co-founder and CEO of Bybit. “We are incredibly grateful for their trust and remain committed to providing best-in-class, reliable services tailored to local needs. Bybit actively collaborates with regulators worldwide to ensure compliance and responsible innovation.”
Looking Forward: Bridging the Gap to Web3
Bybit has consistently been at the forefront of Web3 innovation, reshaping how users interact with the blockchain ecosystem through user-centric and engaging platforms. In 2024, we have expanded our suite of offerings with breakthrough solutions like the Airdrop Arcade, NFT Pro, and Inscription Marketplaces.
These platforms are meticulously designed not only to lower entry barriers and simplify the user experience but also to enrich it by curating opportunities to invest in and support a diverse range of promising, trending, and blue-chip tokens and projects. Our most recent Solana Fiesta and Bitcoin economy livestream introduced many Web3-curious individuals to the fast-growing ecosystems and their opportunities.
This curation consistently ensures that our users have access to the most rewarding and reliable opportunities in the Web3 space, making participation not only easier but also more enjoyable through gamification and advanced data intelligence. This commitment extends to the upcoming launch of Bybit Web3 DEX Pro, a cutting-edge decentralized exchange platform powered by revolutionary i-SMART data intelligence technology. This represents Bybit’s commitment to innovation that empowers, providing tools that not only meet but exceed the needs of modern traders and investors.
“Today’s milestone signifies more than just numbers; it’s a testament to our ongoing dedication to revolutionizing the crypto landscape,” emphasized Zhou. “Bybit remains committed to shaping the future of crypto. We will continue to uphold the values of listening, caring, and improving, to serve our 30 million users with the most professional products. Protecting the interests of our clients will be ingrained in all product designs. We envision a world where Web3 empowers every individual, where financial inclusivity is not just a goal but a reality.”
The post Bybit Reaches 30 Million Registered Users, Marking Explosive Growth and Industry Leadership into Web3 appeared first on HIPTHER Alerts.

 
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Next Generation Drug Conjugates Market – By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Next Generation Drug Conjugates Market is valued at US$ 2.61 Bn in 2023, and it is expected to reach US$ 7.94 Bn by 2031, with a CAGR of 15.1% during the forecast period of 2024-2031.
Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482
Next Generation Drug Conjugates Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 2.61 Bn

Revenue Forecast In 2031

USD 7.94 Bn

Growth Rate CAGR

CAGR of 15.1% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type, By Targeting Ligand, By Payload, By Therapy, By Route of Administration, By Indications and By Region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Growth of the next-generation drug conjugates market is driven by several factors, such as the recent accelerated approvals of various next-generation drug conjugates and the keen interest shown by the big pharma players in forging strategic alliances with the next-generation drug conjugate developers.
The ever-growing rise in medicare costs, along with the increasing burden of rare disease indications, prompted the stakeholders to look for alternatives to conventional therapies. As a result, the next-generation conjugates combine cytotoxic drugs with targeting agents, enhancing drug efficacy while reducing systemic toxicity. Deeper cellular penetration and permeability have emerged as viable targeted therapeutics for rare disease indications, including cancers.
List of Prominent Players in the Next Generation Drug Conjugates Market:

Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
Dyne Therapeutics, Inc.
Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
Vincerx Pharma
Tubulis Technologies
Nurix Therapeutics, Inc.
Other Prominent Players

Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2482
Market Dynamics:
Drivers:
The growth of the next generation drug conjugates (NGDCs) market is driven by several key factors. Technological advancements, such as improved linker technologies and versatile applications, enhance drug efficacy and safety.
The rising prevalence of chronic diseases, particularly cancer and genetic disorders, fuels demand for targeted therapies. Strategic industry collaborations and acquisitions, like Pfizer’s purchase of Seagen, accelerate innovation and market expansion. Favorable regulatory environments support expedited review processes and clear development guidelines. Additionally, significant investment in research and development, supported by funding and innovative platforms, drives the discovery and optimization of new NGDCs. These combined factors contribute to the rapid advancement and adoption of NGDCs in modern medicine.
Challenges:
The global next-generation drug conjugates market faces several formidable challenges. One of the primary obstacles is the high development cost associated with these therapies. The complex manufacturing processes required for drug conjugates involve sophisticated technology and stringent quality control measures, making scalability difficult and expensive. Additionally, the regulatory landscape presents significant hurdles; furthermore, gaining permission from regulatory bodies like the FDA and EMA is a time-consuming and expensive process that frequently necessitates substantial clinical trials to prove safety and efficacy.
Another major challenge is ensuring the stability and efficacy of drug conjugates. In order to be effective, these therapies must both release the therapeutic agent at the target site in a controlled manner and be stable under physiological conditions. Balancing these requirements while minimizing toxicity is a complex scientific and technical task. Patents and proprietary technology can restrict the capacity of new companies to enter the market and innovate, which further complicates intellectual property issues.
Regional Trends:
The North American next generation drug conjugates market is growing due to advanced healthcare infrastructure and significant R&D investments. Key players in the region are driving innovation in targeted cancer therapies, leveraging cutting-edge technologies for drug conjugation. The increasing cases of cancer and the rising demand for personalized medicine boost the market. Favorable regulatory policies further stimulate market growth, allowing swift approval and commercialization of novel drug conjugates.
Moreover, strategic collaborations between pharmaceutical companies and research institutions fuel the development of next-generation therapies. With a robust pipeline and expanding applications beyond oncology, the North American market for drug conjugates is poised for sustained expansion.
Curious About This Latest Version of The Report? Enquiry Before Buying:https://www.insightaceanalytic.com/enquiry-before-buying/2482
Recent Developments:

In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company involved in the growth of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.
In March 2023, Japan-based PeptiDream signed strategic partnership with US-based RayzeBio to develop a peptide-radioisotope (RI) conjugate against Glypican-3 (“GPC3”) expressed in liver cancers.
In March 2023, The USFDA accepted Ionis Pharmaceutical’s New Drug Application (NDA) for its investigational antisense medication Eplontersen, which is intended for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from Alnylam, Eplontersen will be the second medication licensed for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

For More Customization @ https://www.insightaceanalytic.com/customisation/2482
Segmentation of Next Generation Drug Conjugates Market-
Next Generation Drug Conjugates Market- By Type

Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand-mediated RNAi Conjugate
Ligand Conjugated Antisense Medicine
Peptide Drug Conjugate

Next Generation Drug Conjugates Market- By Targeting Ligand

Amino Sugar
Lipid
Peptide
Small Molecule
Virus-like Particles

Next Generation Drug Conjugates Market- By Payload

Peptide
Small Molecule
Oligonucleotide
Radionuclide

Next Generation Drug Conjugates Market- By Therapy

Monotherapy
Combination Therapy

Next Generation Drug Conjugates Market- By Route of Administration

Intravenous
Subcutaneous
Others

Next Generation Drug Conjugates Market- By Indications

Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Familial Chylomicronemia Syndrome
Alpha-1 Antitrypsin Deficiency Liver Disease

Next Generation Drug Conjugates Market- By Region
North America–

The US
Canada
Mexico

Europe–

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific–

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Latin America–

Brazil
Argentina
Rest of Latin America

 Middle East & Africa–

GCC Countries
South Africa
Rest of Middle East and Africa

Why should buy this report:

To receive a comprehensive analysis of the prospects for global next generation drug conjugates market
To receive industry overview and future trends of global next generation drug conjugates market
To analyze the next generation drug conjugates market drivers and challenges
To get information on the next generation drug conjugates market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisition in global next generation drug conjugates market industry

Other Related Reports Published by InsightAce Analytic:
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market 
Conjugation and Labeling Services Market 
Peptide–Drug Conjugates (PDCs) Market
Antibody Discovery Market
The post Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd. appeared first on HIPTHER Alerts.

 
The IRS Criminal Investigation (CI) unit is responsible for conducting financial crime investigations, including tax fraud, money laundering, public corruption, and more. There are several methods that they may use to uncover financial crimes. However, the data available to CI through the Banking Secrecy Act (BSA) has proven to be one of their most powerful tools in uncovering instances of tax evasion.
CI relies heavily on BSA data, with nearly 88% of its criminal tax investigations in fiscal year 2023 involving individuals or entities with a BSA filing. BSA data has proven instrumental in allowing CI to execute substantial asset seizures and secure increased convictions. With a federal conviction rate of nearly 90% and a presence across the U.S. and internationally, CI is dedicated to prosecuting tax criminals and maintaining the integrity of the financial system.
If you need help resolving your civil or criminal tax exposure issues, get help from our Dual-Licensed Tax Lawyers & CPAs by calling the Tax Law Offices of David W. Klasing today at (800) 681-1295 or click here to schedule a reduced rate initial consultation.
IRS Criminal Investigation Unit’s Use of BSA Data
IRS CI recently disclosed using Bank Secrecy Act (BSA) data in combating financial crimes, underscoring its effectiveness in investigations. According to CI, in fiscal year 2023, nearly 88% of the investigations initiated by the agency involved individuals or entities with a BSA filing. This highlights the critical role BSA data plays in uncovering financial wrongdoing across various sectors.
Impact on Financial Crime Investigations
From FY21 to FY23, CI reports that BSA data played a pivotal role in securing significant outcomes in financial crime investigations. Notably, it contributed to an average prison sentence of 39 months for convicted individuals and the seizure of $7.4 billion in assets linked to criminal activities. Furthermore, restitution orders totaling $434 million and forfeited assets totaling $629 million were attributed to BSA data, representing substantial increases compared to previous fiscal years.
Diverse Application in Investigations
CI Chief Jim Lee emphasized the versatility of BSA data in uncovering a wide array of financial crimes, including those related to COVID relief programs, skimming schemes, and employment tax fraud. Among investigations originating from BSA data in FY23, approximately 77% relied on information from suspicious activity reports, while 63.6% utilized data from currency transaction reports. Additionally, fraudulent Small Business Association loans tied to COVID relief programs, skimming incidents, and employment tax fraud constituted significant portions of investigations leveraging BSA data.
CI’s Jurisdiction and Achievements
As the law enforcement arm of the IRS, CI holds jurisdiction over a range of financial offenses, including tax fraud, narcotics trafficking, money laundering, and public corruption. Notably, CI boasts a federal conviction rate of nearly 90%, a testament to its effectiveness in prosecuting offenders. With 20 field offices across the United States and 12 attaché posts internationally, CI maintains a robust presence in combating financial crimes both domestically and abroad.
Accordingly, if you are concerned that you may be accused of a tax crime, then you must seek legal support. Our Dual-Licensed Tax Lawyers & CPAs can help assess your case and identify the proper course of action. We will work diligently protect your interests and reduce or eliminate the potential penalties you face.
What is the Banking Secrecy Act?
The BSA is a U.S. federal law enacted in 1970 aimed at combating money laundering and other financial crimes. It requires financial institutions to assist government agencies in detecting and preventing money laundering by maintaining records of cash purchases over $10,000, filing reports of cash transactions exceeding this amount, and filing suspicious activity reports (SARs) for transactions that appear to be connected to illicit activities. The BSA also imposes requirements on financial institutions to verify the identity of customers and maintain effective anti-money laundering programs.
Methods the IRS Criminal Investigation Unit Uses to Uncover Tax Crimes
Ultimately, there are several strategies that the CI may use to uncover tax crimes. For instance, charges may stem from any of the following:
Review of Tax Returns and Documentation
IRS Criminal Investigation meticulously reviews tax returns and supporting documentation to detect discrepancies and irregularities that may indicate tax crimes. By cross-referencing reported income with other financial records and conducting thorough examinations of tax filings, CI can identify inconsistencies or fraudulent activities, laying the groundwork for further investigation and potential prosecution.
Analysis of Offshore Accounts and Complex Financial Structures
CI specializes in scrutinizing offshore accounts and complex financial structures utilized by individuals and entities to conceal income and evade taxes. Through comprehensive analysis of international financial transactions and collaborations with foreign tax authorities, CI can uncover hidden assets and income streams, exposing tax evasion schemes and holding perpetrators accountable for their actions.
Cooperation with Informants and Whistleblowers
CI may collaborate with informants and whistleblowers who provide insider information on tax crimes. These individuals, often with knowledge of fraudulent activities, can assist CI in gathering evidence and identifying key players involved in tax evasion schemes, enhancing the agency’s ability to investigate and prosecute offenders effectively.
Surveillance and Undercover Operations
In certain cases, CI may conduct surveillance and undercover operations to gather evidence of tax crimes. This may involve monitoring suspect individuals or businesses to observe their financial activities and interactions, providing CI with valuable insights into potential tax evasion or fraudulent behavior that can be used in criminal investigations and prosecutions.
Partnerships with Other Law Enforcement Agencies
CI frequently partners with other law enforcement agencies, both domestically and internationally, to uncover and combat tax crimes. By sharing information and resources, CI can leverage the expertise and capabilities of partner agencies to conduct comprehensive investigations, track down tax evaders, and bring them to justice.
Monitoring Social Media Activity
Finally, CI may monitor social media activity to gather intelligence and evidence related to tax crimes. By analyzing publicly available information, including posts, photos, and interactions, CI agents can identify individuals flaunting lavish lifestyles inconsistent with reported income or engaging in activities suggestive of tax evasion. This information can provide valuable leads for further investigations and enforcement actions against tax offenders.
Contact Our Attorneys for Help with Your Tax Issue
If you have failed to file a tax return for one or more years or have taken a position on a tax return that could not be supported upon an IRS or state tax authority audit, eggshell audit, reverse eggshell audit, or criminal tax investigation, it is in your best interest to contact an experienced tax defense attorney to determine your best route back into federal or state tax compliance without facing criminal prosecution.

Note:  

As long as a taxpayer that has willfully committed tax crimes (potentially including non-filed foreign information returns coupled with affirmative evasion of U.S. income tax on offshore income) self-reports the tax fraud (including a pattern of non-filed returns) through a domestic or offshore voluntary disclosure before the IRS has started an audit or criminal tax investigation / prosecution, the taxpayer can ordinarily be successfully brought back into tax compliance and receive a nearly guaranteed pass on criminal tax prosecution and simultaneously often receive a break on the civil penalties that would otherwise apply. 
It is imperative that you hire an experienced and reputable criminal tax defense attorney to take you through the voluntary disclosure process. Only an Attorney has the Attorney Client Privilege and Work Product Privileges that will prevent the very professional that you hire from being potentially being forced to become a witness against you, especially where they prepared the returns that need to be amended, in a subsequent criminal tax audit, investigation or prosecution.
Moreover, only an Attorney can enter you into a voluntary disclosure without engaging in the unauthorized practice of law (a crime in itself). Only an Attorney trained in Criminal Tax Defense fully understands the risks and rewards involved in voluntary disclosures and how to protect you if you do not qualify for a voluntary disclosure.
As uniquely qualified and extensively experienced Criminal Tax Defense Tax Attorneys, Kovel CPAs and EAs, our firm provides a one stop shop to efficiently achieve the optimal and predictable results that simultaneously protect your liberty and your net worth.   See our Testimonials to see what our clients have to say about us!

We Are Here for You
Regardless of your business or estate needs, the professionals at the Tax Law Offices of David W. Klasing are here for you. We are open for business and our team will help ensure that your business is too. Contact the Law Offices of David W. Klasing today to discuss your business with one of our professionals.
In addition to our fully staffed main office in downtown Irvine California,  the Tax Law Offices of David W. Klasing has unstaffed (conference room only) California based satellite offices in Los Angeles, San Bernardino, Santa Barbara, Panorama City, Oxnard, San Diego, Bakersfield, San Jose, San Francisco, Oakland, Carlsbad, Sacramento. We also have unstaffed (conference room only) satellite offices in Las Vegas Nevada, Salt Lake City Utah, Phoenix Arizona & Albuquerque New Mexico, Austin Texas, Washington DC, Miami Florida and New York New York that solely handle Federal & California Tax issues.
Our office technology allows clients to meet virtually via GoToMeeting. With end-to-end encryption, strong passwords, and top-rated reliability, no one is messing with your meeting. To schedule a reduced rate initial consultation via GoToMeeting follow this link. Call our office and request a GoToMeeting if you are an existing client.  We also now offer a convenient scheduling option, where you can secure David W. Klasing, Esq M.S.-Tax CPA’s undivided attention for a 4-hour consultation at any of his satellite offices.
See our Audit Representation Q and A Library
See our Criminal Tax Law Q and A Library
See our Non-Filer Q and A Library
Public Contact: Dave Klasing Esq. M.S.-Tax CPA, [email protected]
SOURCE Tax Law Offices of David W. Klasing, PC
The post From the Tax Law Offices of David W. Klasing – The Importance of Bank Secrecy Act Data in IRS Criminal Investigations of Tax Crimes appeared first on HIPTHER Alerts.